Comparison
GlaxoSmithKline Pakistan Limited vs Hoechst Pakistan Limited
GlaxoSmithKline Pakistan Limited (GLAXO) is worth Rs 99.4 bn at the latest close, 2.6 times the market value of Hoechst Pakistan Limited (HPL) at Rs 38.9 bn. In their latest annual results GLAXO reported revenue of Rs 65.9 bn (FY2025) and HPL Rs 31.0 bn (FY2025). GLAXO trades at 9.5× earnings and HPL at 10.4×. Dividend yields: GLAXO 5.4%, HPL 6.0%.
| Latest | GLAXO FY2025 | HPL FY2025 |
|---|---|---|
| Price | Rs 312.07 | Rs 4,030.00 |
| Market value | Rs 99.4 bn | Rs 38.9 bn |
| P/E | 9.5× (stronger) | 10.4× |
| P/B | 2.89× (stronger) | 4.55× |
| Dividend yield | 5.4% | 6.0% (stronger) |
| Revenue (latest year) | Rs 65.9 bn | Rs 31.0 bn |
| Revenue growth, year on year | 7.7% | 15.7% (stronger) |
| Revenue growth, 5 years a year | 13.4% | 17.0% (stronger) |
| Profit (latest year) | Rs 10.0 bn (stronger) | Rs 2.9 bn |
| EPS (latest year) | Rs 31.48 | Rs 300.69 |
| Dividend per share | Rs 17.00 | Rs 240.00 |
| Net margin | 15.2% (stronger) | 9.4% |
| Return on equity | 32.4% | 38.6% (stronger) |
| Debt to equity | 1.1% (stronger) | 3.2% |
| Current ratio | 2.32× (stronger) | 1.71× |
| Dividend streak (years) | 2 | 3 (stronger) |
Highlighted: the higher figure where higher is usually stronger (growth, margins, returns, yield) or the lower where lower is (P/E, P/B, debt). A highlight is a comparison, not a recommendation.
GLAXO
GlaxoSmithKline Pakistan Limited financial statements →
HPL
Hoechst Pakistan Limited financial statements →
Related comparisons
Prices at the latest close; financial figures from each company's latest annual report. Information only, not investment advice.